Companies · Co-founded · Multiple Exits
The companies co-founded and operated across three decades. Exit detail captured row by row.
Founded 1995. Dallas. Private family office investing personal capital in FDA-regulated frontier biotech. Active. Read Andrew Hillman, Principal of Hillman Ventures.
2007 to 2010. Co-founder. FDA-regulated specialty healthcare services. Exited to Dynacq Healthcare (NASDAQ: DYII).
2011 to 2016. Co-founder. Rehabilitation services platform. Exited to Next Health.
2012 to 2017. Co-founder. Pharmaceutical wholesale distribution. Exited to
Next Health (LinkedIn).
2012 to 2020. Co-founder. CLIA Highly Complex toxicology laboratory. Exited to Critical Healthcare Ltd, UK.
2007 to 2014. Co-founder. Specialty pharmacy services. Exited to
Pharma Holdings U.S.
1998 to 2005. Co-founder. Healthcare claims processing. Exited to The Alpha Group (TAG).
Co-founder, Partner, and Investor. Texas hospital network with locations in Plano, Houston (Texas Medical Center), San Antonio (two facilities, one converted from a former HealthSouth hospital and one new-construction on the North Side), McKinney, Fort Worth (including a downtown location), East Houston, and Beaumont, with corporate offices in The Woodlands.
Mesenchymal exosome biologics on the 351(a) BLA pathway. Targeted Osmotic Lysis for solid tumors with an academic medical foundation.
Exosome and mesenchymal stem cell-derived extracellular vesicle products are not approved by the FDA for any indication. References here describe published scientific literature. They do not describe an available treatment. Targeted Osmotic Lysis is investigational. It has not been approved by the FDA for any indication and it is not available as a treatment.